Celldex says an­ti­body drug im­proves ir­ri­ta­ble skin con­di­tion in Phase 2 test

Celldex said its mon­o­clon­al an­ti­body has shown en­cour­ag­ing ef­fi­ca­cy in a mid-stage tri­al in pa­tients with an in­flam­ma­to­ry skin con­di­tion that fea­tures hives and swelling …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER